Information Provided By: 
Fly News Breaks for March 8, 2017
REGN
Mar 8, 2017 | 06:22 EDT
Piper Jaffray analyst Edward Tenthoff continues to expect Regeneron Pharmaceuticals will win FDA approval of Dupixent in atopic dermatitis by the March 29 action date. The lack of an FDA advisory panel and updated Phase III data at the American Academy of Dermatology meeting enhance the analyst's confidence in approval. Tenthoff sees long-term value for Dupixent with approvals in broader allergic indications and reiterates an Overweight rating on Regeneron shares with a $446 price target.
News For REGN From the Last 2 Days
REGN
Apr 26, 2024 | 08:41 EDT
Oppenheimer analyst Hartaj Singh raised the firm's price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1 earnings report on May 2. Oppenheimer believes the areas of focus will be the status and dynamics of the Eylea High Dose launch, questions around the impending Dupixent COPD PDUFA, the status of the two oncology approvals expected in 2024, updates on various pipeline projects in immunology and oncology, and comments on capital allocation and financial planning by the new CFO at the company.
REGN
Apr 25, 2024 | 07:28 EDT
